Bicara Therapeutics (BCAX) Cash & Equivalents (2023 - 2026)

Bicara Therapeutics has reported Cash & Equivalents for 4 years, with the latest figure at $323.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 30.0% year-over-year to $323.5 million; the trailing twelve-month figure through Mar 2026 stood at $323.5 million (down 30.0% YoY), and the FY2025 full-year result was $96.7 million, down 80.26% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $323.5 million, up from $96.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $520.8 million in Q3 2024, with the low at $96.7 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $341.4 million across 4 years, with a median of $380.0 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 112.51% — and 2025, when it sank 80.26%.
• Bicara Therapeutics' Cash & Equivalents stood at $230.4 million in 2023, then surged by 112.51% to $489.7 million in 2024, then slumped by 80.26% to $96.7 million in 2025, then jumped by 234.55% to $323.5 million in 2026.
• The last three Cash & Equivalents figures came in at $323.5 million (Q1 2026), $96.7 million (Q4 2025), and $171.7 million (Q3 2025), per Business Quant data.